RhumbLine Advisers
DRUG

RhumbLine Advisers’s Bright Minds Biosciences DRUG Stock Holding History

RhumbLine Advisers’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$566K Buy
7,762
+1,826
+31% +$147K ﹤0.01% 2539
2025
Q4 		$463K Sell
5,936
-640
-10% -$42.8K ﹤0.01% 2710
2025
Q3 		$399K Sell
6,576
-36
-0.5% -$1.4K ﹤0.01% 2842
2025
Q2 		$173K Buy
+6,612
New +$198K ﹤0.01% 3307

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

RhumbLine Advisers's DRUG Position: Q1 2026 in Review

RhumbLine Advisers increased its Bright Minds Biosciences (DRUG) stake by 31% in Q1 2026, buying an estimated $147K and bringing the position to 7,762 shares worth $566K. The position accounts for ﹤0.01% of the portfolio, ranked #2539.

RhumbLine Advisers first reported a position in DRUG in Q2 2025 and has held it in 4 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • RhumbLine Advisers held 7,762 shares of Bright Minds Biosciences worth $566K as of Q1 2026.
  • RhumbLine Advisers bought 1,826 Bright Minds Biosciences shares in Q1 2026, an estimated $147K.
  • Bright Minds Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2539 holding.
  • RhumbLine Advisers first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 4 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.